Female Genital Schistosomiasis (FGS) is a severe public health issue that affects millions of women, particularly in rural Africa, where healthcare access is often limited. Caused by the parasitic worm Schistosoma haematobium, FGS is a major cause of pain, infertility, and predisposes women of reproductive age to an increased risk of HIV infection and cervical cancer. Despite millions of women at risk, FGS remains underdiagnosed and inadequately treated, thus revealing significant gaps in gender equality in healthcare access. While effective preventive treatments like praziquantel are available, access is limited due to the low awareness among communities and healthcare providers, combined with insufficient resources for effective delivery. Integrated health interventions and targeted outreach efforts, including scaling up existing treatment solutions, could offer a lifeline to millions of vulnerable women, as we advocate for research and development of point of care diagnostics and treatments.